Dräger makes changes to Executive Board

Carla Kriwet will take responsibility for marketing and sales on 1 January 2011

The Supervisory Board of Drägerwerk Verwaltungs has appointed Dr Carla Kriwet as a new Executive Board member, who will take responsibility for marketing and sales on 1 January 2011.

Kriwet currently works for Linde Group as head of Healthcare Europe for the Division Hospital Care and Homecare in Central and Northern Europe.



Dr Dieter Pruss, currently responsible for marketing and sales for the safety division on the Executive Board, will leave the company at his own request on 31 December, 2010, to take on new challenges. 


You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Personal Protection

Draeger introduces X-plore 8000 powered air purifying respirator

To help workers in the pharmaceutical sector breathe easy in harsh environments

DRAEGER OFFERS FREE COPIES OF NEW DRÄGERTUBE HANDBOOK

<p>Draeger is offering a free copy of the new DraegerTubes & CMS-Handbook to anyone with a need for short term gas detection. Available whilst stocks last, this 15th edition is packed with the latest information on more than 350 DraegerTubes and represents a definitive guide to the selection and use of short term tubes in line with current legislation.</p>

Easy infra-red upgrade and longer sensor life with explosion-proof Draeger Sensor IR

<p>Upgrading to infra-red technology has never been easier, or more cost effective, than with the longer-life, explosion-proof Draeger Sensor IR. </p>
Sustainability

Explosion-proof transmitter from Draeger

<p>Draeger Safety has launched the Draeger PIR 3000, a smart explosion proof infra-red gas transmitter that the company says ensures reliable detection of combustible gases and vapours.</p>
Research & Development

DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children

The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year
Research & Development

Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling

The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry
Subscribe now